Skip to main content
ARS Home » Northeast Area » Boston, Massachusetts » Jean Mayer Human Nutrition Research Center On Aging » Research » Publications at this Location » Publication #403489
Research Project: Nutrition, Sarcopenia, Physical Function, and Skeletal Muscle Capacity During Aging

Location: Jean Mayer Human Nutrition Research Center On Aging

Title: Novel potential targets for function-promoting therapies: orphan nuclear receptors, anti-inflammatory drugs, troponin activators, mas receptor agonists, and urolithin A

Author
item DIOH, WALY - BIOPHYTIS
item NARKAR, VIHANG - UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER
item SINGH, ANURAG - AMAZENTIZ
item MALIK, ANDY - CYTOKINETICS, INC.
item FERRUCCI, LUIGI - NATIONAL INSTITUTE ON AGING (NIA, NIH)
item TOURETTE, CENDRINE - BIOPHYTIS
item MARIANI, JEAN - BIOPHYTIS
item VANMAANEN, ROB - BIOPHYTIS
item FIELDING, ROGER - JEAN MAYER HUMAN NUTRITION RESEARCH CENTER ON AGING AT TUFTS UNIVERSITY

Submitted to: Journal of Gerontology Medical Science
Publication Type: Review Article
Publication Acceptance Date: 1/31/2023
Publication Date: 6/16/2023
Citation: Dioh, W., Narkar, V., Singh, A., Malik, A., Ferrucci, L., Tourette, C., Mariani, J., Vanmaanen, R., Fielding, R.A. 2023. Novel potential targets for function-promoting therapies: orphan nuclear receptors, anti-inflammatory drugs, troponin activators, mas receptor agonists, and urolithin A. Journal of Gerontology Medical Science. https://doi.org/10.1093/gerona/glad072.
DOI: https://doi.org/10.1093/gerona/glad072

Interpretive Summary:

Technical Abstract: Background: In recent years, several new classes of therapies have been investigated with their potential for restoring or improving physical functioning in older adults. These have included: Mas receptor activators, regulators of mitophagy, skeletal muscle troponin activators, anti-inflammatory compounds, and targets of orphan nuclear receptors. Methods: Review of literature. Results: The present article summarizes recent developments of the function promoting effects of these exciting new compounds and shares relevant pre-clinical and clinical data related to their safety and efficacy. Conclusions: The development of novel compounds in this area and expanding and likely will need to the advent of new treatment paradigm for age-associated mobility loss and disability.